| Ident. | Authors (with country if any) | Title |
|---|
| 000086 |
Stéphane Thobois [France] ; Eugénie Lhommee [France] ; Hélène Klinger [France] ; Claire Ardouin [France] ; Emmanuelle Schmitt [France] ; Amélie Bichon [France] ; Andrea Kistner [France] ; Anna Castrioto [France] ; JING XIE [France] ; Valerie Fraix [France] ; Pierre Pelissier [France] ; Stephan Chabardes [France] ; Patrick Mertens [France] ; Jean-Louis Quesada [France] ; Jean-Luc Bosson [France] ; Pierre Pollak [France] ; Emmanuel Broussolle [France] ; Paul Krack [France] | Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil |
| 000856 |
Dieter Scheller [Allemagne] ; PIU CHAN [République populaire de Chine] ; QIN LI [Royaume-Uni] ; TAO WU [République populaire de Chine] ; RENLING ZHANG [République populaire de Chine] ; LE GUAN [République populaire de Chine] ; Paula Ravenscroft [Royaume-Uni] ; Celine Guigoni [France] ; Alan R. Crossman [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France] | Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease |
| 000A33 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 000A35 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000C14 |
Paula Ravenscroft [Royaume-Uni] ; Sylvie Chalon [France] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] | Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia |
| 000D49 |
Roberto Maggio [Italie] ; Marco Scarselli [Italie] ; Francesca Novi [Italie] ; Mark J. Millan [France] ; Giovanni U. Corsini [Italie] | Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole |
| 000D51 |
Christian E. Gross [France] ; Paula Ravenscroft [France] ; Sandra Dovero [France] ; Mohamed Jaber [France] ; Bernard Bioulac [France] ; Erwan Bezard [France] | Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice |
| 000D57 |
Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France] | Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole |
| 000E79 |
P. Sokoloff [France] ; J.-C. Schwartz [France] | The dopamine D3 receptor and its implication in neuropsychiatric disorders and their treatments |
| 000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
| 001172 |
L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
| 001242 |
D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
| 001396 |
P. Sokoloff [France] ; J. Diaz [France] ; R. Bordet [France] ; N. Griffon [France] ; S. Perachon [France] ; C. Pilon [France] ; S. Ridray [France] ; J.-C. Schwartz [France] | Fonction et potentialités thérapeutiques du récepteur D3 de la dopamine : Du gène au comportement : nouveau cheminement en direction de nouveaux agents psychotropes |
